Prevention of autoimmune diabetes by ectopic pancreatic β-cell expression of interleukin-35

Diabetes

Volumn 61, Issue 6, 2012, Pages 1519-1526

  Bettini, Maria ^a   Castellaw, Ashley H ^a   Lennon, Greig P ^a   Burton, Amanda R ^a   Vignali, Dario A A ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE 6 PHOSPHATASE; INTERLEUKIN 35;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTOIMMUNE DISEASE; BIOLOGICAL ACTIVITY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL INFILTRATION; CELL POPULATION; CELL PROLIFERATION; DIABETES MELLITUS; G1 PHASE CELL CYCLE CHECKPOINT; INSULITIS; MOUSE; NONHUMAN; PANCREAS ISLET BETA CELL; PREVENTION STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANIMALS; CD8-POSITIVE T-LYMPHOCYTES; CELL PROLIFERATION; DIABETES MELLITUS, TYPE 1; FEMALE; GENE EXPRESSION; INSULIN-SECRETING CELLS; INTERLEUKINS; MICE; MICE, INBRED NOD; MICE, TRANSGENIC; T-LYMPHOCYTES;

EID: 84861851646     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db11-0784     Document Type: Article

References (27)

1. Atkinson MA, Eisenbarth GS. Type 1 diabetes: new perspectives on disease pathogenesis and treatment. Lancet 2001;358:221-229 (Pubitemid 32718550)
2. Bettini M, Vignali DA. Regulatory T cells and inhibitory cytokines in autoimmunity. Curr Opin Immunol 2009;21:612-618
3. Atkinson MA, Leiter EH. The NOD mouse model of type 1 diabetes: as good as it gets? Nat Med 1999;5:601-604 (Pubitemid 29289413)
4. Luo X, Herold KC, Miller SD. Immunotherapy of type 1 diabetes: where are we and where should we be going? Immunity 2010;32:488-499
5. Chuang YP, Chu CH, Sytwu HK. Genetic manipulation of islet cells in autoimmune diabetes: from bench to bedside. Front Biosci 2008;13:6155-6169
6. Sung HH, Juang JH, Lin YC, et al. Transgenic expression of decoy receptor 3 protects islets from spontaneous and chemical-induced autoimmune destruction in nonobese diabetic mice. J Exp Med 2004;199: 1143-1151
7. Mueller R, Krahl T, Sarvetnick N. Pancreatic expression of interleukin-4 abrogates insulitis and autoimmune diabetes in nonobese diabetic (NOD) mice. J Exp Med 1996;184:1093-1099 (Pubitemid 26313566)
8. Grewal IS, Grewal KD, Wong FS, et al. Expression of transgene encoded TGF-beta in islets prevents autoimmune diabetes in NOD mice by a local mechanism. J Autoimmun 2002;19:9-22 (Pubitemid 35205196)
9. Mueller R, Bradley LM, Krahl T, Sarvetnick N. Mechanism underlying counterregulation of autoimmune diabetes by IL-4. Immunity 1997;7:411-418 (Pubitemid 27446015)
10. Collison LW, Chaturvedi V, Henderson AL, et al. IL-35-mediated induction of a potent regulatory T cell population. Nat Immunol 2010;11:1093-1101
11. Collison LW, Workman CJ, Kuo TT, et al. The inhibitory cytokine IL-35 contributes to regulatory T-cell function. Nature 2007;450:566-569 (Pubitemid 350190247)
12. Leiter EH. The NOD mouse: a model for insulin-dependent diabetes mellitus. Curr Protoc Immunol 2001;Chapter 15:Unit 15.9
13. Moon JJ, Chu HH, Pepper M, et al. Naive CD4(+) T cell frequency varies for different epitopes and predicts repertoire diversity and response magnitude. Immunity 2007;27:203-213 (Pubitemid 47284919)
14. Holst J, Szymczak-Workman AL, Vignali KM, Burton AR, Workman CJ, Vignali DA. Generation of T-cell receptor retrogenic mice. Nat Protoc 2006; 1:406-417
15. Burton AR, Vincent E, Arnold PY, et al. On the pathogenicity of autoantigen-specific T-cell receptors. Diabetes 2008;57:1321-1330
16. Szymczak AL, Workman CJ, Wang Y, et al. Correction of multi-gene deficiency in vivo using a single 'self-cleaving' 2A peptide-based retroviral vector. Nat Biotechnol 2004;22:589-594 (Pubitemid 38585911)
17. Szymczak AL, Vignali DA. Development of 2A peptide-based strategies in the design of multicistronic vectors. Expert Opin Biol Ther 2005;5:627-638 (Pubitemid 40780547)
18. Grewal IS, Grewal KD, Wong FS, Picarella DE, Janeway CA Jr, Flavell RA. Local expression of transgene encoded TNF alpha in islets prevents autoimmune diabetes in nonobese diabetic (NOD) mice by preventing the development of auto-reactive islet-specific T cells. J Exp Med 1996;184: 1963-1974 (Pubitemid 26404486)
19. Gallichan WS, Kafri T, Krahl T, Verma IM, Sarvetnick N. Lentivirus-mediated transduction of islet grafts with interleukin 4 results in sustained gene expression and protection from insulitis. Hum Gene Ther 1998;9:2717-2726 (Pubitemid 29027015)
20. Thébault-Baumont K, Dubois-Laforgue D, Krief P, et al. Acceleration of type 1 diabetes mellitus in proinsulin 2-deficient NOD mice. J Clin Invest 2003;111:851-857 (Pubitemid 37074960)
21. Moriyama H, Abiru N, Paronen J, et al. Evidence for a primary islet autoantigen (preproinsulin 1) for insulitis and diabetes in the nonobese diabetic mouse. Proc Natl Acad Sci USA 2003;100:10376-10381 (Pubitemid 37071886)
22. Marie JC, Letterio JJ, Gavin M, Rudensky AY. TGF-beta1 maintains suppressor function and Foxp3 expression in CD4+CD25+ regulatory T cells. J Exp Med 2005;201:1061-1067 (Pubitemid 40524674)
23. Amrani A, Verdaguer J, Serra P, Tafuro S, Tan R, Santamaria P. Progression of autoimmune diabetes driven by avidity maturation of a T-cell population. Nature 2000;406:739-742
24. Bettini M, Szymczak-Workman AL, Forbes K, et al. Cutting edge: accelerated autoimmune diabetes in the absence of LAG-3. J Immunol 2011;187: 3493-3498
25. Falcone M, Yeung B, Tucker L, Rodriguez E, Krahl T, Sarvetnick N. IL-4 triggers autoimmune diabetes by increasing self-antigen presentation within the pancreatic Islets. Clin Immunol 2001;98:190-199
26. Peng Y, Laouar Y, Li MO, Green EA, Flavell RA. TGF-beta regulates in vivo expansion of Foxp3-expressing CD4+CD25+ regulatory T cells responsible for protection against diabetes. Proc Natl Acad Sci USA 2004;101:4572-4577 (Pubitemid 38437452)
27. Jones LL, Vignali DA. Molecular interactions within the IL-6/IL-12 cytokine/receptor superfamily. Immunol Res 2011;51:5-14